Know Cancer

or
forgot password

Validation of Circulating Biomarkers Using the Immunological Multiparameter Chip Technology (IMPACT) on Plasma Specimens Collected on CALGB 80303


N/A
18 Years
N/A
Not Enrolling
Both
Pancreatic Cancer

Thank you

Trial Information

Validation of Circulating Biomarkers Using the Immunological Multiparameter Chip Technology (IMPACT) on Plasma Specimens Collected on CALGB 80303


OBJECTIVES:

- To determine whether the observed predictive value of plasma VEGF-A and VEGF-R2 for
overall survival (OS) in study BO17706 can be replicated in study CALGB-80303 using the
same Immunological Multiparameter Chip Technology (IMPACT) assay.

- To determine whether the observed predictive value of plasma VEGF-A and VEGF-R2 for
progression-free survival (PFS), and other circulating biomarkers in study BO17706, can
be replicated in study CALGB-80303 using the same IMPACT assay.

- To explore the relationship between efficacy and other biomarkers measured in the
plasma samples.

OUTLINE: The samples required for this study are stored in the CALGB Pathology Coordinating
Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No
additional samples are required from patients.

The following markers are analyzed in EDTA plasma samples using the Immunological
MultiParameter Chip Technology (IMPACT) a Roche proprietary multiplex enzyme-linked
immunosorbent assay (ELISA) platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3,
IL-8, bFGF, PDGF-C, ICAM-1, and PlGF.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Patients must have been registered to CALGB-80303

- Histologically or cytologically confirmed adenocarcinoma of the pancreas

- Locally advanced or metastatic disease

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Median OS/PFS (95% CI) estimated from Kaplan-Meier curves for patients with low and patients with high biomarker levels

Safety Issue:

No

Principal Investigator

Herbert Pang, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

CALGB Statistical Office at Duke University Medical Center

Authority:

United States: Institutional Review Board

Study ID:

A151201

NCT ID:

NCT01664169

Start Date:

Completion Date:

Related Keywords:

  • Pancreatic Cancer
  • adenocarcinoma of the pancreas
  • recurrent pancreatic cancer
  • stage III pancreatic cancer
  • stage IV pancreatic cancer
  • stage IIB pancreatic cancer
  • Pancreatic Neoplasms

Name

Location